Disabling Abl—Perspectives on Abl kinase regulation and cancer therapeutics

This publication has 15 references indexed in Scilit:

• Autoinhibition of c-Abl
  Cell, 2002
• Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
  Science, 2001
• Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia Chromosome
  New England Journal of Medicine, 2001
• Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia
  New England Journal of Medicine, 2001
• The Tyrosine Kinase Abl-Related Gene ARG Is Fused toETV6 in an AML-M4Eo Patient With a t(1;12)(q25;p13): Molecular Cloning of Both Reciprocal Transcripts
  Blood, 1999
• Structural basis for selective inhibition of Src family kinases by PP1
  Chemistry & Biology, 1999
• An intramolecular SH3-domain interaction regulates c-Abl activity
  Nature Genetics, 1998
• Oligomerization of the ABL Tyrosine Kinase by the Ets Protein TEL in Human Leukemia
  Molecular and Cellular Biology, 1996
• Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells
  Nature Medicine, 1996
• RETRACTED: Selective inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyrimidine class.
  Proceedings of the National Academy of Sciences, 1995